Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PNMT | P11086 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413319 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BTAAR1SLC6A2 | |
| SCHEMBL31054190 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BTAAR1SLC6A2 | |
| SCHEMBL31054149 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BTAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL5962875 | 0.98 | HTR2A (0.96) | HTR2AHTR2CHTR2BTAAR1SLC6A2 | |
| SCHEMBL23979286 | 0.94 | HTR2A (0.89) | HTR2AHTR2CHTR2BTAAR1SLC6A2 | |
| SCHEMBL17407614 | 0.85 | HTR2A (0.73) | HTR2AHTR2CHTR2BCYP2A6SIGMAR1 | |
| SCHEMBL3677922 | 0.83 | HTR2A (0.71) | HTR2AHTR2CHTR2BCYP2A6SIGMAR1 | |
| SCHEMBL15131790 | 0.82 | HTR2A (0.70) | HTR2AHTR2CHTR2BTAAR1CYP2A6 | |
| SCHEMBL27827005 | 0.82 | HTR2A (0.68) | HTR2AHTR2CHTR2BTAAR1SLC6A2 | |
| SCHEMBL24548518 | 0.81 | HTR2A (0.68) | HTR2AHTR2CHTR2BCYP2A6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | claimed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | claimed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| EP-3455203-B1 | VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS | RES TRIANGLE INST (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190225573-A1 | VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS | RES TRIANGLE INST (US) | 2019-07-25 | — | — | US | disclosed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017197101-A1 | VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS | RESEARCH TRIANGLE INSTITUTE (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| US-7071225-B2 | Arylaminopropane analogues and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2006-07-04 | — | — | US | disclosed |
| CN-1512879-A | Novel arylaminopropane analogues and their use for treatment of glaucoma | �Ƹ��� | 2004-07-14 | — | — | CN | disclosed |
| US-20040110791-A1 | Novel arylaminopropane analogues and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-10 | — | — | US | disclosed |
| US-6346402-B1 | ACTS ON OPTICALLY ACTIVE (S)-ALPHA-PHENETHYLAMINE AND PYRUVIC ACID TO FORM ACETOPHENONE AND ALANINE; FOR PRODUCING CHEMICAL INTERMEDIATES OF DRUGS AND AGRICULTURAL CHEMICALS | KANEKA CORPORATION (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-1045025-A1 | (S)-alpha-PHENETHYLAMINE : PYRUVATE TRANSAMINASE | KANEKA CORPORATION (JP) | 2000-10-18 | — | — | EP | disclosed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225573-A1 | VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS | SLC18A2, SLC6A2, SLC18A3 | HTR2A 10/4885HTR2C 11/4885HTR2B 16/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | HTR2A 4044/4885HTR2C 3776/4885HTR2B 2765/4885 |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | BRCA1, VHL, TP53 | HTR2A 3785/4885HTR2C 4143/4885HTR2B 4393/4885 |
| US-20040110791-A1 | Novel arylaminopropane analogues and their use for the treatment of glaucoma | PDE3A, PDE2A, PDE3B | HTR2A 1384/4885HTR2C 2209/4885HTR2B 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.